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ABSTRACT 
Nonribosomal peptides contain a wide range of unusual non-proteinogenic amino acids residues. As a 
result these complex secondary metabolites are amongst the most structurally diverse secondary 
metabolites in nature and possess a broad spectrum of biological activities. β-Hydroxylation of amino 
acid precursors or peptidyl residues and their subsequent processing by downstream tailoring enzymes 
is one of the most common themes in the biosynthetic-diversification of these therapeutically 
important natural products. Identification and characterisation of the biosynthetic intermediates and 
enzymes involved in these processes is thus pivotal in understanding nonribosomal peptide assembly 
and is essential for efforts aimed at re-programming the biosynthetic machinery to produce new 
variants with improved properties. Previously we identified two genes asnO and hasP, from the 
calcium dependent antibiotic (CDA) biosynthetic gene cluster within Streptomyces coelicolor. We 
predicted, from in silico analysis, that these genes encode an asparaginyl oxygenase (AsnO) and a 3-
hydroxyasparaginyl phosphotransferase (HasP) which are responsible for the biosynthesis 3-
hydroxyasparaginyl (3-OHAsn) and 3-phosphohydroxyasparagine (3-OPAsn) present within the 
lipopeptide core of CDA variants. To test this hypothesis we separately deleted hasP and asnO from 
the S. coelicolor chromosome. Whilst the wild-type strains produce a number of 3-OHAsn and 3-
OPAsn CDAs the ΔhasP mutants produce exclusively non-phosphorylated variants (3-OHAsn).  The 
ΔasnO mutants, on the other hand, produce several new Asn containing CDA variants that are not 
present in the wild-type. These results confirm the in vivo function of these gene products. To explore 
the timing of the hydroxylation and phosphorylation reactions both genes were expressed in E. coli and 
the protein products where subjected to in vitro assays with a range of Asn derivatives and Asn 
containing peptides, including CDA variants. None of these potential substrates were transformed by 
the enzymes, which might suggest that the true substrates of AsnO and HasP remain tethered the 
peptidyl carrier protein domain within the nonribosomal peptide synthetase assembly-line. 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
The calcium dependent antibiotics (CDA) from Streptomyces coelicolor (Hojati, 2002; Kempter, 1997) 
belong to the group of structurally related acidic lipopetide antibiotics, which include A54145 
(Fukuda, 1990; Miao, 2006), daptomycin (Baltz, 2005; Miao, 2005; Raja, 2003), friulimicins and 
amphomycins (Vértesy, 2000). All of these nonribosomally biosynthesised lipopeptides contain N-
terminal fatty acid side chains, which is a trans-2,3-epoxyhexanoyl moiety in the case of CDA (Fig. 1), 
along with decapeptide lactone or lactam cores. Within the decapeptide cores are a number of common 
amino acids, including acidic residues responsible for co-ordination of calcium ions, which is essential 
for antimicrobial activity. Notably, daptomycin was recently approved for clinical use, becoming the 
first new structural class of natural antibiotics to reach the clinic in over 30 years (Baltz, 2005; Raja, 
2003). As a result of this, there has been considerable interest in establishing the biosynthetic origins 
of the acidic lipopeptide group of antibiotics, with the specific aim of engineering new lipopeptide 
variants with improved therapeutic properties. To this end we have focused on engineering the 
biosynthesis of CDA, using adenylation domain active site modifications to replace Asp at postion 7 in 
CDA with Asn (Uguru, 2004) and a mutasynthesis approach to replace the D-hydroxyphenylglycine 
(D-HPG) at position 6, with alternative arylglycines (Hojati, 2002).    
 In addition to D-HPG, CDA contains a number of other non-proteinogenic amino acids 
including L-3-methylglutamic acid (3-MeGlu, position 10), which is also present at the same relative 
position in the decapeptide cores of daptomycin and A54145, and a C-terminal Z-dehydrotryptophan 
residue (Hojati, 2002). In addition to this CDA variants, are known which contain either (2R, 3S)-3-
hydroxyasparagine (3-OHAsn) or (2R, 3S)-3-phosphohydroxyasparagine (3-OPAsn) at position 9. 
Whilst 3-OHAsn is common to a number of peptides antibiotics including A54145 (Fukuda, 1990; 
Miao, 2006), katanosin B (Kato, 1988) and ramoplanin (Walker, 2005; McCafferty 2002), 3-
phosphohydroxyasparagine has not been found else where in nature, to date.  
Previously we analysed the cda biosynthetic gene cluster and identified a gene SCO3236 which 
encodes a protein that shows high similarity to clavaminate synthase (CAS), an Fe(II)/α-ketoglutarate 
dependent oxygenase from Streptomyces clavuligerus. CAS catalyses the β-hydroxylation of the 
arginine side chain of deoxyguanidinoproclavaminic acid and subsequent cyclisation and 
dehydrogenations steps during the biosynthesis of clavulanic acid (Baldwin, 1993; Salowe, 1990). On 
this basis we suggested that SCO3236 encodes an asparagine oxygenase (AsnO) which we predicted 
would catalyse the β-hydroxylation of an Asn residue in a CDA precursor to generate the (2R, 3S)-3-
hydroxyasparagine found in CDA (3a, 3b, 4a and 4b variants) (Fig 1).  
β-Hydroxylation of amino acids is a common phenomenon in the biosynthesis of nonribosomal 
peptides (Chen, 2001). Indeed the subsequent processing of the amino acid β-hydroxyl groups by 
further oxidation (Chen 2002), glycosylation (Lu, 2004), macrolactonisation (Walker, 2005; 
McCafferty 2002, Kato, 1988), methylation (Maio, 2006) or in the case of CDA phosphorylation 
serves to increase the structural diversity of nonribosomal peptides and related products resulting in a 
wide range of biological activities. Of the many β-hydroxylated amino acids and derivatives found in 
nonribosomal peptides some arise as result of the oxidation of free amino acids prior to peptide 
assembly (Yin, 2004; Ju, 2004; Haltli, 2005). For example in the biosynthesis of viomycin and 
mannopeptimycin L-Arg and the non-proteinogenic amino acid L-enduracididine are hydroxylated as 
free amino acids by non-heme Fe(II), α-ketoglutarate dependent oxygenases VioC (Yin, 2004; Ju, 
2004) and MppO (Haltli, 2005) respectively. In addition there are number of other non-heme Fe(II), α-
ketoglutarate dependent oxygenases which are known to hydroxylate specific amino acid residues 
within ribosomal polypeptides. For example mammalian asparaginyl hydroxylases EGFH and FIH are 
known which catalyse the postranslational β-hydoxylation of Asn residues within epidermal growth 
factor (EGF) domains (Jia, 1994) and the hypoxia-inducible factor (HIF) C-terminal transactivation 
domains (Hewitson, 2002). Finally several monooxygenase enzymes have been characterised that 
function on amino acid thioesters that are tethered to carrier proteins via flexible phosphopantetheine 
prosthetic groups (Chen, 2001 & 2002). These include heme protein hydroxylases (ORF20, NovI, & 
NikQ) which are responsible for the β-hydroxylation of PCP-tethered tyrosine and histidine residues 
during the biosynthesis of chloroeremomycin, novobiocin (Chen 2001) and nikkomycin (Chen, 2002). 
Downstream of asnO, in the CDA gene cluster, is a gene SCO3234 which codes for a protein 
that shows sequence similarity to a number of ATP-dependent aminoglycoside phosphotransferases, 
including SpcN which has been shown to phosphorylate spectinomycin as part of the host self-
resistance mechanism in the producer strain Streptomyces flavopersicus (Lyutzkanova, 1997). Based 
on this we suggested that the SCO3234 gene product is a putative 3-hydroxyasparagine 
phosphotransferase (HasP), which phosphorylates the 3-hydroxyasparaginyl residue of CDA3a/b and 
CDA4a/b resulting in the 3-phospho-hydroxyasparaginyl residues found in CDA1b and CDA2a/b (Fig 
1). In this paper we aim to determine the in vivo function of the asnO and hasP gene products and test 
the hypothesis that these products are involved in the sequential hydroxylation and phosphorylation of 
the asparaginyl residues in CDA. It was envisaged that this insight may provide a means to control the 
functionality of the Asn derived residues in CDA which could be further utilised to engineer other 
therapeutically relevant acidic lipopeptides based round the A54145 and daptomycin structural 
templates. 
 
 
 
METHODS 
Bacterial strains, plasmids and culture conditions. The bacterial strains and plasmids used in this 
study are listed in table 1. E. coli strains were propagated routinely in Luria broth (LB), or on agar 
plates at 37 °C. For DNA manipulation Streptomyces strains were routinely propagated in YEME 
liquid media or on R2YE agar plates at 30°C (Kieser, 2000) Antibiotics were used in selective media 
at the following concentrations: ampicillin at 100 µgml-1; kanamycin at 50 µgml-1; and 
chloramphenicol at 34 µgml-1 for E. coli;  with apramycin at 100 µgml-1; thiostrepton at 5 µgml-1; and 
hygromycin at 200 µgml-1 for Streptomycetes. X-Gal and IPTG were added to LB-agar plates at a 
concentration of 40 µgml-1 and 20 mM respectively, to detect the loss of lacZ α-complementation in E. 
coli XL1-Blue (Bullock, 1987) carrying pGEM T-Easy derived plasmids (Promega).  
 
DNA preparation amplification and sequencing. S. coelicolor cosmids were obtained from the John 
Innes Centre, Norwich. Cosmid ScE29 encompassed (SCO3234 and SCO3236) of the CDA gene 
cluster, and was isolated from E. coli using the Qiagen Midiprep Kit (Qiagen). Small-scale plasmid 
preparation was carried out using the alkaline lysis method (Birnboim, 1979), unless a higher quality 
of DNA was required for sequencing, in which case DNA was prepared using a Midiprep Kit 
(Qiagen). Streptomyces genomic DNA was prepared as described previously (Kieser, 2000). 
Restriction enzymes were purchased from Roche, New England Biolabs and MBI Fermentas. Alkaline 
phosphatase, T4 DNA ligase and Pwo polymerase were all purchased from Roche. All enzymes were 
used according to the manufacturers recommendations unless otherwise specified. 
 PCR amplification was carried out on a GeneAmp PCR system 2400 (Perkin Elmer) using 100 
pmol of each primer, ca. 100 ng of cosmid or 200 ng genomic DNA template per 100 µl reaction and 1 
unit of the high fidelity Pwo polymerase. PCR reactions also contained 5 % (v/v) DMSO to overcome 
potential secondary structure formation in the G/C rich Streptomyces DNA. Following amplification, 
PCR products were purified using the Qiaquick extraction kit (Qiagen). PCR products and primers 
used in this work are detailed in Table 2. DNA sequencing of PCR products was carried out using the 
chain termination method using the ABI/PRISM dye terminator cycle sequencing core kit (Perkin-
Elmer). E. coli plasmid construction and transformations where carried out using standard procedures 
(Sambrook, 2000). 
 
Construction of the asnO deletion cassette. An upstream region of SCO3236 was PCR amplified 
using primers AsnOF2 and AsnOR2, containing Xho I and Pst I respectively (Table 2), with ScE29 as 
a template to generate a 1558 bp amplicon (fragment A) containing the first 226 bp of SCO3236. 
Fragment A and pMT3000 (Paget, 1994) were digested with Xho I and Pst I and ligated to form 
plasmid pJN9a. Primers AsnOF3 and AsnOR3, containing EcoR I and Xho I restriction sites, were 
used in a PCR reaction with ScE29 as a template to generate a 1662 bp amplicon (fragment B)  
containing the last 227 bp of SCO3236. Fragment B and pMT3000 were digested with EcoR I and Xho 
I and ligated to form pJN9b. Fragment A was excised from pJN9a via Pst I/ Xho I and ligated into 
similarly digested pJN9b, to give the plasmid pJN10 containing the asnO (AB) deletion construct (Fig. 
2). This was excised from pJN10 via the flanking Bgl II sites and ligated into the BamH I site of 
pKC1132 (Bierman, 1992), resulting in pJN12 which was used for delivery of the truncated asnO into 
the chromosome of S. coelicolor 2377 (Hopwood, 1983) and MT1110 (Hindle, 1994) strains.  
 
Construction of the hasP deletion cassette. An upstream region of SCO3234 was PCR amplified 
using primers HasPF1 & HasPR1, containing Pst I and Xba I restriction sites respectively, with ScE29 
as a template to generate a 1830 bp amplicon (fragment A´) containing the first 70 bp of SCO3234. 
Fragment A´ and pMT3000 were digested with Pst I and Xba I and ligated to form pMUT1. Primers 
HasPF2 & HasPR2, containing Xba I and Xho I restriction sites respectively, and the template ScE29 
were used in the PCR amplification of a 1939 bp amplicon (fragment B´). containing the last 215 bp of 
SCO3234. Fragment B´ and pMT3000 were digested with Xba I and Xho I and ligated to form 
pMUT2, excised from pMUT2 via Xba I/ Xho I and ligated into similarly digested pMUT1, to give the 
plasmid pLG3 containing the hasP deletion construct (A´B´) (Fig. 2). The deletion construct was 
excised from pLG3 via the flanking Bgl II sites and ligated into the BamH I site of pMAH (Paget, 
1994), resulting in pLG4, which was used for delivery of the truncated hasP into the chromosome of S. 
coelicolor 2377 and MT1110 strains.  
 
Deletion of asnO and hasP from S. coelicolor MT1110 and 2377 
ΔasnO and ΔhasP delivery plasmids pJN12 and pLG4 was first passed through E. coli strain ET12567 
to remove Dam/Dcm methylation. The plasmids were then alkaline denatured as described previously 
(Oh, 1997) and introduced into Streptomyces protoplasts prepared as described earlier (Okanishi,1974) 
using the PEG mediated method (Kieser, 2000). Primary integrants of pJN12 and pLG4 were selected 
for with apramycin and hygromycin respectively, and grown for two generations on non-selective agar 
to allow for a double crossover event. Recombinants were screened for the loss of antibiotic resistance 
by replica plating. Total genomic DNA was isolated from recombinants, and used as a template for 
PCR amplification using primers flanking the deleted region. Primers 29.05seqF2 and 29.05R2 
amplified the region of asnO, giving products of size 1044 bp from strains that had reverted to wild 
type and 495 bp from strains that had a truncated form of asnO (Fig. 3A). Similarly, primers HasPKO1 
and HasPKO2 were used to amplify the region of hasP, resulting in products of size 1818 bp in the 
wild type strains and 1200 bp in the strains that contained a truncated form of hasP (Fig. 3B).  DNA 
sequencing of PCR products corresponding to truncated forms of asnO and hasP was also carried out, 
confirming that an in-frame deletion of 528 bp of the asnO and 618 bp of hasP genes had occurred 
(data not shown). Two S. coelicolor 2377-∆asnO strains and four S. coelicolor MT1110-∆asnO strains 
were generated, whilst three S. coelicolor 2377-∆hasP and S. coelicolor MT1110-∆hasP strains were 
generated.  
 
CDA production extraction and analysis. The MT1110 wild type, ΔasnO and ΔhasP mutant strains 
were grown were grown in parallel for 6 days at 30°C in SV2 liquid medium (Hojati, 2002). S. 
coelicolor 2377 wild type, ΔasnO and ΔhasP mutant strains were similarly grown were grown for 6 
days at 30 °C in SM22 liquid medium (Hojati, 2002). The culture supernatants were acidified to pH 2 
with 0.5 M aq. HCl and passed through Varian MegaBond Elute SPE cartridges (Varian Inc.) as 
described previously (Hojati, 2002). The CDA extracts were then eluted with 40 % acetonitrile in H2O 
and dried under reduced pressure. LC-MS Analysis of the crude extracts was carried out on a 
Micromass LCT orthogonal acceleration time of flight mass spectrometer equipped with an 
electrospray ionization source run in positive mode, combined with a Waters 2790 separation module. 
Gradient elution was carried out on a Luna C18 150 x 4.6 mm 3µ analytical column (Phenomenex). 
Solvent A was 0.1 % formic acid and solvent B was Acetonitrile/0.1% formic acid. A gradient of 20 % 
B rising to 70 % over 10 min, followed by 100 % B held for 5 min at a flow rate of 1 mlmin-1 was 
applied. Amanda expand and add details: A sample CDA6a was purified by semi-preprative HPLC 
and analysed by high resolution MS using an FTICR. CDA6a was also treated with NaOH aq. (X mM) 
to genertate the linear form which was sequenced by MS-MS again using an FTICR. 
 
Recomplementation of S. coelicolor 2377 and MT1110 ∆ asnO mutants with plasmid-borne asnO 
To construct a Streptomyces expression plasmid bearing AsnO, the gene sequence was PCR amplified 
from cosmid ScE29 with primers 29.05F2 and 29.05R2, Containing restriction sites Xho I and Nde I 
respectively. The purified product was restricted and ligated into E. coli expression vector pET-15b, 
resulting in the 6708 bp plasmid pJN14. AsnO was digested from pJN14 by digestion with BamH I and 
Xho I and ligated into restriction digested pIJ6021 (Takano, 1995), resulting in the 8904 bp plasmid 
pJN15. The ligation products were used to transform S. lividans 1326, and positive transformants were 
selected by growth on medium containing kanamycin. pJN15 was prepared from positive clones, 
checked by restriction analysis, and introduced into S. coelicolor ∆asnO mutants by protoplast 
transformation. The plasmid-complemented mutants were cultivated in SV2 medium supplemented 
with kanamycin and thiostrepton was added at a concentration of 10 µgml–1 to induce expression of 
AsnO. CDA was purified from the culture supernatant and analysed by LC-MS as described 
previously.  
Cell-based bioassay of Asn containing CDAs. Spores of S. coelicolor wild type and ∆asnO derived 
mutant strains were used to inoculate nutrient agar plates in the presence and absence of Ca2+ (12 mM). 
After 2 days incubation at 30°C an overnight culture of the CDA sensitive B. mycoides indicator strain 
was used to overlay the plates in soft nutrient agar (per litre: 13g Nutrient Broth, 7g Bactoagar). 
Calcium-dependent bioactivity was observed as a zone of inhibition after one night of incubation at 
30°C. 
 
Amanda Check this: Well-based bioassay of Asn containing CDAs. 2ml of an overnight culture of 
the CDA sensitive strain B. mycoides was used to seed nutrient agar plates in the presence and absence 
of Ca2+ (12 mM). Agar plugs were cut from the dried plates using a cork borer creating wells into 
which 100 µl CDA6a (1 m/ml) was added. After refrigeration for 2 hours to allow for diffusion of the 
antibiotic the plates were incubated at 30°C overnight, after which time calcium dependent bioactivity 
was seen as zones of inhibition.  
 
Protein expression procedures. hasP was PCR amplified from cosmid ScE29 as a 963 bp fragment 
using primers cdaforw2 (containing Nde I) and cdaprev2 (containing BamH I) with Pwo polymerase, 
and ligated into the pGEM-T Easy PCR cloning vector (Promega), resulting in the 3978 bp plasmid 
pLG1. hasP was Nde I/BamH I restricted from pLG1 as a 939 bp fragment and ligated into pET-15b. 
The resulting plasmid pLG2 and the corresponding asnO expression vector pJN14, also derived from 
pET-15b contained the complete gene sequences of hasP and asnO respectively, including the start 
and stop codons, and an N-terminal His-tag. The plasmids were expressed in E. coli BL21 (DE3) 
pLysS cells (Studier, 1996) at 30°C and 25°C respectively, by addition of 1 mM IPTG. The 37 kDa 
AsnO and 36 kDa HasP were then partially purified under native conditions by nickel chelate 
chromatography. Analysis of proteins was carried out by SDS-PAGE and Western analysis was carried 
out using a penta-His antibody (Qiagen) and an anti-mouse IgG secondary antibody (Pierce) 
conjugated to an alkaline phosphatase, with detection using the substrate BCIP/NBT (Sigma).  (Fig. 7). 
Protein concentration was determined using the Bradford assay and the A640 measured in a microtitre 
plate reader. 
 
In vitro protein assays. AsnO was desalted and concentrated on a centrifugal filter unit (Millipore). 
Individual reactions containg 20 µg of AsnO, 5 mM Asn containing substrates (see results section), 1 
mM or 10 mM iron (II) sulphate, 5 mM α-ketoglutarate and 50 mM Tris-Cl (pH 7.8), with and without 
the addition of 1 mM ascorbate (sodium salt) and 0.5 mM DTT in a final volume of 250 µl. were 
incubated at 30°C for with 1 hour in closed tubes. Reaction mixtures were then applied to a Microcon 
centrifugal filter unit (Millipore) to remove protein from the reaction products, which were analysed 
by LC-MS. HasP cell-free extract (containing 40 µg protein) was incubated in a 100 µl reaction 
containing 5 mM CDA4b, 25 mM ATP, 10 mM MgCl2, and 25 mM Tris-Cl (pH 7.5) for 30 minutes at 
30°C in closed tubes. Reactions were worked up and analysed by LC-MS as described above. 
 
RESULTS 
AsnO and HasP sequence analysis.  
Up-to-date BLAST sequence similarity searches on the SCO3236 (asnO) and SCO3234 (hasP) gene 
products were performed. In the case of HasP no recently deposited protein sequences, in addition to 
the aminoglycoside phosphotransferases noted earlier (Hojati, 2002), were identified which might 
provide insight into the function of the putative phosphotransferase. On the other hand several new 
sequences, in addition to clavaminic acid synthase (CAS), were identified which exhibit high 
similarity to the putative asparagine oxygenase (AsnO). For example, LptL, which is predicted to be 
involved in the hydroxylation of the Asn residue at position 3 of A54145 in Streptomyces fradiae 
(Miao, 2006), possesses 45% identity across 310 out of 330 amino acids residues. In addition L-
enduracididine hydroxylase, VioC (Yin, 2004; Ju, 2004), exhibits 33% identity across a 292 amino 
acid overlap with AsnO, and the L-Arg hydroxylase MppO (Haltli, 2005) possesses 31% identity 
across 300 amino acid residues. All of these proteins possess the His-1 (HXE) and the C-terminal His-
3 (DNXXXXH) motifs which make up the Fe(II) coordination sphere which is consistent with their 
known or putative function as Fe(II)/α-ketoglutarate dependent oxygenase enzymes (Khaleeli, 2000; 
Haltli, 2005) (Amanda expand on this as the extra information will go in your thesis) 
 
Generation of S. coelicolor ∆asnO and ∆hasP mutants 
In order to establish the role of the asnO and hasP gene products both genes were separately deleted 
from the S. coelicolor chromosome using a standard double crossover recombination approach (Keiser, 
2000). In brief, upstream and downstream flanking sequences of approximately 2 kb and including the 
start and stop codon of the gene to be truncated respectively were PCR amplified (see Table 2). The 
fragments were ligated into Streptomyces non-replicating integrative vectors (see Table 1), for delivery 
into the chromosome of S. coelicolor strains 2377 (Hopwood, 1983) and MT1110 (Hindle, 1994) (Fig 
2). Primary integrants were selected using an appropriate antibiotic, and double crossover 
recombinants were screened for loss of antibiotic resistance after 2 rounds of growth on solid media. 
The successful generation of the required in-frame mutants was confirmed by PCR amplification 
across the truncated region (Fig. 2) followed by DNA sequencing. Knockout experiments were 
performed in both 2377 and MT1110 strains, since these strains have different growth media 
requirements and produce different profiles of CDAs. The combined information can thus provide 
valuable complementary information which can assist in validating the results of the separate 
experiments.  
 
Analysis of S. coelicolor ∆hasP and ∆asnO and bioassays of Asn containg CDA. 
The S. coelicolor 2377 wild type strains and ΔhasP derived mutant strains were grown in liquid culture 
under conditions that are favourable for phosphorylated CDA production and the supernatants were 
analysed by LC-MS. This confirmed the previous observation (Hojati, 2002) that the wild type 2377 
produces predominantly D-3-phosphohydroxyasparagine containing peptide CDA2b as the major 
product, along with a minor amount of D-3-hydroxyasparagine variants CDA4b and CDA3b (Fig. 4A). 
In contrast the 2377-ΔhasP mutants  produced only the non-phosphorylated variants CDA3b and 
CDA4b (Fig 4B). Indeed, repeated fermentation and analysis of several 2377-ΔhasP mutant strains 
clearly revealed a complete absence of CDA2b, or any other phosphorylated CDAs. This supports the 
hypothesis that the gene product HasP is the CDA 3-hydroxyasparaginyl phosphotransferase. Analysis 
of the wild-type MT1110, grown on a variety of different media, showed only D-3-hydroxyasparagine 
containing CDAs and failed to reveal any phosphorylated CDAs. Comparison of the phenotype change 
between the wild type and MT1110−ΔhasP was therefore not possible in this case.  
S. coelicolor MT1110 wild-type and MT1110-ΔasnO mutant strains were grown in liquid 
media under identical parallel conditions. LC-MS analysis of the wild-type MT1110 revealed the 3-
MeGlu containing peptide CDA4a as the major product along with a minor amount of the Glu 
containing CDA3a (Fig. 5A). However, the mutant MT1110-ΔAsnO does not produce any wild-type 
CDA, common to the wild type variants (Hojati, 2002; Kempter, 1997), but instead exhibits a major 
new product with retention time 6.86 min which exhibited protonated, sodiated and potassiated 
molecular ions in the ESI-MS consistant with mw 1478 Da (Fig 5B). This CDA variant was therefore 
assigned as non-hydroxylated asparagine containing variant CDA6a (Fig.1), which is related to 
CDA4a by the loss of the oxygen (1494-16 Da). Similarly, the S. coelicolor 2377 wild-type and 2377-
ΔasnO mutant strains were grown in liquid culture. As above the wild-type 2377 produced CDA2b as 
the major product with a minor amount of CDA4b and 3b. In contrast, the mutant 2377-ΔasnO 
produced none of the previously characterized CDAs. Instead two new products were identified with 
unique retention times of 6.79 and 6.90 minutes, with molecular ions in the ESI-MS which are 
consistent with new CDA variants of molecular weights 1466 and 1480 Da respectively (Fig 5C). The 
slower eluting variant thus corresponds to a non-hydroxylated variant, of CDA3b (1482-16Da), which 
we have assigned as CDA5b (Fig 1). The faster eluting product is consistent with a non-hydroxylated 
variant of CDA4b (1496-16Da) and was assigned as CDA6b. It is thus clear from these 
complementary results that deletion of asnO abolishes the normal CDA production profile of OH-Asn 
and PO-Asn containing peptides and instead results in the production of a group of previously 
uncharacterised Asn containing CDA variants (designated CDA5b, 6b and 6a).  
Amanda: discuss HRMS-FTICR and MS-MS-FTICR data. 
 
 
Expression of plasmid-borne asnO in the of ∆asnO mutants 
In order to gain further confirmation that AsnO is responsible for the hydroxylation of the Asn residue 
in CDA, the ΔasnO mutants were recomplemented by transformation with a thiostrepton inducible 
asnO expression vector derived from the Streptomyces plasmid pIJ6021. Accordingly the plasmid-
complemented 2377 and MT1110 ∆asnO mutants were grown on media containing the inducer 
thiostrepton. LC-MS analysis of the extracts revealed the same CDA profile as the wild type with the 
2377-∆asnO recomplemented strain producing mainly 3-hydroxyasparagine containing CDA3b and 
4b. Similary the MT1110-∆asnO recomplemented strain produced CDA4a, which also contains 3-
hydroxyasparagine at position 9. The results of the asnO knockout and recomplementation 
experiments are thus entirely consistent with the AsnO, a single polypeptide, functioning as an 
asparaginyl oxygenase. 
 
Bioactivity of Asn CDAs 
S. coelicolor 2377 and MT110 wild type and ∆asnO derived mutant strains were incubated in the 
presence and absence of Ca2+ and overlaid with the CDA sensitive strain B. mycoides. A calcium 
dependent zone of inhibition was seen around the two S. coelicolor 2377-∆asnO strains indicating that 
Asn containing CDAs retained activity (fig. 6). Similarly, all four of the S. coelicolor MT1110-∆asnO 
strains retained calcium dependent activity (data not shown). Amanda include bioassay of pure 
CDA6a Generate the figure ! 
 
AsnO and HasP protein expression, purification and assays 
AsnO and HasP were overproduced in E. coli BL21 (DE3) on the his6-tag expression vectors pET-15b 
(Novagen). Expression was induced by addition of IPTG and purification was carried out by Nickel 
chelate chromatography under native conditions. Analysis of proteins by SDS-PAGE and Western 
blots were consistent with the calculated mw of the proteins AsnO (37 kDa) and HasP (36 kDa). The 
AsnO protein was incubated with a variety of Asn derivatives, including L-asparagine, N-acetyl-L-
asparagine, L-asparaginamide; N-acetyl-L-asparaginamide, along with the corresponding (D) 
enatiomers. In addition the peptides L-Asp–L-Gly–L-Asn–L-Glu–L-Trp and L-Asp–L-Gly–D-Asn–L-
Glu–L-Trp as well as crude mixtures of Asn containing CDAs (CDA5b, 6b and 6a) were also tested as 
substrates, along with co-substrate α-ketoglutarate and essential Fe(II)SO4. Numerous assays under 
conditions that have been used previously in the successful assay of CAS and related Fe(II), α-
ketoglutarate dependent oxygenase enzymes were carried out with and without anti-oxidants ascorbate 
or DTT. However in all cases none of predicted 3-hydroxyasparagine containing products were 
detected by LC-MS. Similarly, in order to assay for HasP activity, E. coli cell free extracts containing 
HasP were prepared and incubated with CDA4b, a non-phosphorylated CDA variants, ATP with 
MgCl2, under conditions that were reported to reconstitute in vitro activity of related 
phosphotransferases such as SpcN (Lyutzkanova, 1997). Again LC-MS, indicated that phosphorylation 
of CDA does not take place under these conditions. 
 
DISCUSSION 
The genes asnO (SCO3236) and hasP (SCO3234) encode proteins that show similarity to known 
Fe(II)/α-ketoglutarate dependent oxygenases and aminoglycoside phosphotransferases respectively. In 
order to confirm the predicted role of the gene products, in the biosynthesis of the 3-
hydroxyasparagine and 3-phosophohyroxyasparaginne in CDA, both genes where deleted from the S. 
coelicolor chromosome of strains 2377 and MT1110. LC-MS analysis of the mutant 2377-ΔhasP 
strain showed production of exclusively non-phosphorylated CDAs, whereas the wild-type under 
identical conditions produces predominantly phosphorylated CDA. Analysis of the 2377 and MT1110-
ΔasnO mutants revealed several new CDA products, previously undetected in the wild-type strains, 
which are consistent with Asn containing lipopeptides CDA5b, 6b and 6a (Fig. 1).  
 Bioassays carried out with extracts from ΔasnO mutant strains and from a pure sample of 
CDA6a indicate that Asn containing CDA retains strong Ca2+ dependent antimicrobial activity. The 3-
OHAsn or 3-POAsn motifs are therefore not essential for calcium binding (Fig 6). Interestingly the β-
OHAsn/Asp groups of epidermal growth factor (EGF) are suggested to be involved in calcium binding 
(Carmen, 1999; Lancaster, 2004). Whilst the results presented here suggest that any functional 
similarity between CDA and EGF may be fortuitous, the possibility that β-hydroxylation of Asn in 
nonribosomal as well as ribosomal peptides is evolutionarily linked to the propensity of the 
hydroxylated peptide products to bind Ca2+ ions can not be completely discounted (Lancaster, 2004). 
(Amanda discuss bioassay data of Asn CDAs vs 3-OHAsn CDAs) 
Whilst the results of this work clearly show that AsnO and HasP are involved in the 
biosynthesis of 3-OHAsn and 3-OPAsn in CDA, they do not indicate whether the hydroxylation and 
phosphorylation reactions take place before, during or after peptide assembly. Despite this, clues about 
the true nature of the substrates for AsnO and HasP can be derived by analysing the amino acid 
specificity conferring code of the module 9 adenylation (A) domain of the nonribosomal peptide 
synthetase (cdaPS2) responsible for activating Asn or its derivatives. Indeed the key 10 active site 
residues of the module 9 A-domain (DLTKIGEVGK) within CdaPS2 show high similarity to many 
other Asn activating A-domains from different sources (Stachelhaus, 1999; Challis, 2000). This 
suggests that L-Asn is first activated by the module 9 A-domain, epimerised by the downstream 
epimerisation (E)-domain and that the resulting D-asparaginyl residue is then hydroxylated by AsnO 
during or after peptide assembly. In further support of this hypothesis, we have shown that it is 
possible to change the active site of the Asp-7 A-domain (at the position underlined: DLTKIGAVNK) 
to match exactly the architecture of the module 9 (Asn) A-domain (DLTKIGEVGK). The resulting 
mutant produces a new lipopeptide product, CDA-7N, with Asn at position 7 instead of Asp (Uguru, 
2004). Clearly, if free Asn were hydroxylated to 3-OHAsn prior to A-domain activation then this 
experiment would have resulted in CDAs with 3-OHAsn or 3-OPAsn at position 7 which was not the 
case.  
In order to further explore the issue of the timing of the hydroxylation and phosphorylation 
reactions, the proteins AsnO and HasP were expressed as his6-fusion proteins in E. coli and purified by 
Ni2+-affinity chromatography. In the case of AsnO, L- and D-isomers of Asn, N-acetylasparagine and 
asparaginamide, along with peptides containing both L- and D-Asn where tested as substrates under 
typical conditions that have be used with other Fe(II)/α- ketoglutarate dependent oxygenases. However 
no hydroxylated products were identified. A mixture of crude CDA5b and 6b, containing Asn residues 
at position 9, were also tested as substrates for AsnO, but remained unoxidised. Similarly a sample of 
3-OHAsn failed to be phosphorylated by ATP in the presence of HasP. These findings could be 
explained by the possibility that the asnO and hasP are not functionally expressed in E. coli. Indeed, 
expression of GC rich DNA which contains codons rarely used in E. coli can be problematic. 
Alternatively it is possible that neither free D- or L-Asn derivatives or peptides, including CDAs, 
containing Asn or 3-OHAsn are recognised by the enzymes AsnO or HasP. If this is the case then 
hydroxylation and phosphorylation would be likely to have taken place during peptide assembly. In 
other words, the true substrates of AsnO and HasP may be peptidyl-thioester intermediates tethered to 
one of the peptidyl carrier protein (PCP) domains of the CDA NRPS. Although the β-hydroxylation of 
single amino acids tethered to carrier proteins is well established (Chen, 2001 & 2002), the β-
hydroxylation of amino acid residues within NRPS peptidyl-thioester intermediates, is so far 
unprecedented. However, recently it has been shown that the oxidative phenol coupling reactions, 
occuring in the biosynthesis of vancomycin and related glycopeptide antibiotics, most likely occur on 
the peptidyl-thioester intermediates tethered to PCPs during peptide assembly (Zerbe, 2004; Bischoff, 
2005). The possibility that other classes of oxidative enzymes my similarly process nascent peptidyl 
thioesters during NRPS assembly is therefore a distinct possibility. Clearly the additional 
protein:protein interactions, that would be necessary to facilitate such catalysis, would increase the 
specificity of such enzymes for their non-ribosomal peptidyl substrates, reducing the possibility that 
other ribosomally derived peptide and protein residues might similarly be oxidised to the detriment of 
the host organism. 
In summary we have determined the in vivo functions of asparaginyl oxygenase and a 3-
hydroxyasparaginyl phosphotransferase in CDA biosynthesis. β-hydroxylation of amino acids 
precursors and residues within nonribosomal peptides and their down stream tailoring is common 
theme in nature. Therefore, the results presented here are valuable in furthering our understanding of 
these central biosynthetic-diversification processes. Given that CDA belongs to the therapeutically 
important group of acidic lipopeptides including daptomycin, these insights may also aid future efforts 
aimed engineering new lipopeptide antibiotics for clinical use in humans. 
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Figures and table captions 
 
Table 1. Bacterial strains and plasmids. 
 
Table 2. Primers and PCR products.  
 
Figure 1. Structures of CDA variants. The b series CDA contain L-Trp at position 11, whilst the a 
series possess Z-dehydrotryptophan residues at position 11 (Hojati, 2002; Kempter, 1997). CDA5b, 6a 
and 6b are novel biosynthetically engineered CDAs possessing Asn at position 9 
 
Figure 2. The generation of S. coelicolor ΔasnO and ΔhasP mutant strains was performed using a 
standard double crossover gene replacement strategy, which results in mutants possessing in-frame 
truncated asnO and hasP genes respectively. 
 
Figure 3. PCR analysis of ∆asnO and ΔhasP mutants. (A) lanes 1 and 8: 100 bp molecular weight 
ladder. Lanes 2, 5, 6 & 7: PCR products generated from S. coelicolor MT1110-ΔasnO strains, where 
the major product is of size 495 bp. Lanes 3 & 4: PCR products generated from S. coelicolor MT1110 
wild type strains, where the major product is 1044 bp. (B) lanes 1 and 7: λBstE II molecular weight 
ladder. Lanes 2, 3 & 6: PCR products generated from S. coelicolor MT1110 wild type strains, where 
the major product is of size 1818 bp. Lanes 4 & 5: PCR products generated from S. coelicolor 
MT1110-∆hasP strains, where the major product is 1200 bp.  
 
Figure 4. LC-MS analysis of ΔhasP mutant. (A) S. coelicolor 2377 shows CDA2b (Amanda 
complete: [M+H]+ found 1497.7, requires  xxxx.xx; [M+Na]+ found xxxx.xx, requires xxxx.xx), 
CDA4b ([M+H]+ found 1497.7, requires  xxxx.xx; [M+Na]+ found xxxx.xx, requires xxxx.xx; [M+K]+ 
found xxxx.xx, requires xxxx.xx), CDA3b ([M+H]+ found xxxx.xx, requires  xxxx.xx; [M+Na]+ found 
xxxx.xx, requires xxxx.xx; [M+K]+ found xxxx.xx, requires xxxx.xx).  (B) S. coelicolor 2377-∆ hasP. 
Production of phosphorylated CDA2b is completely abolished in this mutant which produces only 
CDA4b ([M+H]+ found xxxx.xx, requires  xxxx.xx; [M+Na]+ found xxxx.xx, requires xxxx.xx; 
[M+K]+ found xxxx.xx, requires xxxx.xx), CDA3b ([M+H]+ found 1497.7, requires  xxxx.xx; 
[M+Na]+ found xxxx.xx, requires xxxx.xx; [M+K]+ found xxxx.xx, requires xxxx.xx). Rt = retention 
time/min. 
 
Figure 5. LC-MS analysis of ∆asnO mutants. (A) S. coelicolor MT1110 wild-type produces CDA3a 
([M+H]+ found xxxx.xx, requires  xxxx.xx; [M+Na]+ found xxxx.xx, requires xxxx.xx; [M+K]+ found 
xxxx.xx, requires xxxx.xx), CDA4a ([M+H]+ found xxxx.xx, requires  xxxx.xx; [M+Na]+ found 
xxxx.xx, requires xxxx.xx; [M+K]+ found xxxx.xx, requires xxxx.xx). (B) S. coelicolor MT1110-
∆asnO produces CDA3a ([M+H]+ found xxxx.xx, requires  xxxx.xx; [M+Na]+ found xxxx.xx, requires 
xxxx.xx; [M+K]+ found xxxx.xx, requires xxxx.xx). (C) S. coelicolor 2377-∆asnO CDA5b ([M+H]+ 
found xxxx.xx, requires  xxxx.xx; [M+Na]+ found xxxx.xx, requires xxxx.xx; [M+K]+ found xxxx.xx, 
requires xxxx.xx), CDA6b ([M+H]+ found xxxx.xx, requires  xxxx.xx; [M+Na]+ found xxxx.xx, 
requires xxxx.xx; [M+K]+ found xxxx.xx, requires xxxx.xx). Rt = retention time/min. 
 
Figure 6. Bioactivity of Asn containing CDAs. (A) Cell bioassay of 2377-ΔasnO strains overlaid with 
Bacillus mycoides as the indicator strain in the presence of Ca2+ (12 mmol). Strains 13 and 29 are 
∆asnO mutant strains whilst strains 23 and 34 had reverted back to wild type. The wild type strain is 
shown in the centre of the plate.  No zones of inhibition are present in the control plates which contain 
no Ca2+. (B) Well-plate bioassay with pure CDA6a (x µg in 100 µl) and Micrococcus luteus as the 
indicator strain, in the presence of Ca2+ (16 mmol?). Again zones of inhibition are completely absent in 
the control plates which possess no Ca2+. 
 
Figure 7. SDS-PAGE and western analysis of HasP and AsnO proteins overproduced in E. coli. (A) 
SDS-PAGE analysis of His6-tagged HasP. Lane 1: Low range protein markers. Lanes 2-4 show 36 kDa 
HasP fractions following Ni2+ affinity chromatography. (B) Western analysis of the same His6-tagged 
36 kDa HasP fractions following Ni2+ affinity chromatography. (C) Western analysis of His6-tagged 
AsnO. Lane 1: Low range protein markers. Lanes 2-4 show 36 kDa HasP fractions following Ni2+ 
affinity chromatography. 
 
Supplementary: Amanda transplant the DAsnO-recomplementation LC-MS figures into the 
supplementary material 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
  
  
 Figure 1. Structures of CDA variants.  
 
CDAx R6 R9 R10 R11 mw. ref. 
CDA1b OH OPO3H2 H H, H 1562 Kempter, 1997 
CDA2b OH OPO3H2 CH3 H, H 1576 – ı ı – 
CDA3b OH OH H H, H 1482 – ı ı – 
CDA4b OH OH CH3 H, H 1496 – ı ı – 
CDA2a OH OPO3H2 CH3 π-bond 1574 Hojati, 2002 
CDA3a OH OH H π-bond 1480 – ı ı – 
CDA4a OH OH CH3 π-bond 1494 – ı ı – 
CDA5b OH H H H, H 1466 This work 
CDA6b OH H CH3 H, H 1480 – ı ı – 
CDA6a OH H CH3 π-bond 1478 – ı ı – 
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 Figure 3. PCR analysis of ∆asnO and ΔhasP mutants.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
(A) ∆asnO 
 
(B) ∆hasP 
 
CDA2b
time
6.00 7.00 8.00 9.00 10.00 11.00 12.00
0
%
100
m/z
A
CDA4b
m/z
CDA3b
m/z
CDA4b
CDA3b
time
6.00 7.00 8.00 9.00 10.00 11.00 12.00
100
%
0
B
m/z
m/z
Figure 4. LC-MS analysis of !hasP mutant. 
MT1110
CDA3a Rt (6.75)
MT1110-
!asnO
CDA4a Rt (6.86) CDA6a Rt (6.86)
A B
6.00 7.00
%
100 100
%
6.00 7.00
m/z m/z m/z
2377-
!asnO
CDA6b Rt (6.90)
CDA5b Rt (6.79)
C
100
%
6.00
m/z
m/z
7.00
Figure 5. LC-MS analysis of !asnO mutants. 
Amanda
insert
A B
Figure 6. Bioactivity of Asn containing CDA
Figure 7. SDS-PAGE and western analysis of HasP and AsnO proteins  overproduced in E. coli. .
A B
  31 kDa
  45 kDa
66 kDa
  97 kDa
C
HasP
HasP
  31 kDa
  45 kDa
66 kDa
  97 kDa
  21 kDa
  31 kDa
  45 kDa
66 kDa
  97 kDa
  21 kDa
AsnO
 
Table 1. Bacterial strains and plasmids.  
 
Strain and plasmid Genotype, phenotype or characteristics Reference 
 
E. coli XL1-Blue supE+ lac- hsdR17 recA1 F’ proAB+ lacIq lacZ -∆M15 Bullock, 1987 
E. coli BL21 (DE3) pLysS F- ompT hsdSB (rB-mB-) gal dcm (DE3) pLysS Studier, 1986 
E. coli ET 12567 F- dam-13::Tn9 dcm-6 hsdM hsdR recF143 zjj-202::Tn10 
rpsL136 
MacNeil, 1992 
S. coelicolor 2377 hisA1 uraA1 strA1 act-3 SCP1- SCP2+ Hopwood, 1983 
S. coelicolor MT1110 prototrophic SCP1- SCP2- Hindle and 
Smith, 1994 
S. coelicolor 2377 ∆asnO S. coelicolor 2377 with an in-frame deletion of SCO3236 
putative asparaginyl oxygenase. 
This work. 
S. coelicolor MT1110 
∆asnO 
S. coelicolor MT1110 with an in-frame deletion of 
SCO3236 putative asparaginyl oxygenase. 
This work. 
S. coelicolor 2377 ∆hasP S. coelicolor 2377 with a deletion of SCO3234 putative 
asparaginyl phosphotransferase.  
This work. 
S. coelicolor MT1110 
∆hasP 
S. coelicolor MT1110 with a deletion of SCO3234 
putative asparaginyl phosphotransferase. 
This work. 
pGEM T-Easy 3015 bp vector with 3’ - T overhangs, designed for 
cloning PCR products. 
Promega 
pMT3000 2713 bp plasmid derived from pUC-19, where a Xho I site 
has been introduced into the BamH I site of pIJ2925. 
Ampicillin resistant. 
Paget, 1994 
pET-15b 5708 bp E. coli expression vector with an N-terminal his6-
tag. Ampicillin resistant. 
Novagen 
pIJ6021 7800 bp Streptomyces expression vector that includes 
tipA translational codon. Kanamycin and thiostrepton 
resistant, thiostrepton used for induction of expression. 
Takano, 1995 
pMAH 5512 bp E. coli multicopy plasmid and Streptomyces non-
replicating integrative vector. Ampicillin and 
Hygromycin resistant. 
Paget. 1994 
pKC1132 3410 bp E. coli multicopy plasmid and Streptomyces non-
replicating integrative vector derived from pOJ260. 
Apramycin resistant. 
Bierman, 1992 
 
pJN9a pMT3000 containing 1539 bp of the CDA gene cluster 
(Pst I/Xho I), including the first 226 bp and start codon of 
SCO3236 putative asparagine dioxygenase. Ampicillin 
resistant, 4208 bp. 
This work. 
pJN9b pMT3000 containing 1634 bp of the CDA gene cluster 
(EcoR I/Xho I), including the last 227 bp and stop codon 
of SCO323, putative asparaginyl oxygenase. Ampicillin 
resistant, 4320 bp. 
This work.  
pJN10 1539 bp Pst I/Xho I fragment restricted from pJN9a and 
ligated into pJN9b. Ampicillin resistant, 5817 bp. 
This work. 
pJN12 3182 bp Bgl II fragment restricted from pJN10, ligated 
into the BamH I site of pKC1132. Insert contains 
truncated SCO3236, Apramycin resistant, 6592 bp. 
This work. 
pJN14 SCO3236 sequence PCR amplified (1005 bp including 
start and stop codon) and cloned into pET-15b (Nde I/Xho 
This work. 
I). Ampicillin resistant, 6708 bp. 
pJN15 SCO3236 restricted from pJN14 as Xba I/BamH I 
fragment (1110 bp) and ligated into pIJ6021. Kanamycin 
and thiostrepton resistant, 8904 bp. 
This work. 
pMUT1 pMT3000 containing 1819 bp of the CDA gene cluster 
(Pst I/Xba I), including the first 70 bp of SCO3234 
(putative asparaginyl phosphotransferase). Ampicillin 
resistant, 4500 bp.  
This work. 
pMUT2 pMT3000 containing 1928 bp of the CDA gene cluster 
(Xba I/Xho I), including the last 215 bp of SCO3234 
(putative asparaginyl phosphotransferase). Ampicillin 
resistant, 4629 bp. 
This work. 
pLG3 1928 bp Xba I/Xho I fragment restricted from pMUT2 
and ligated into pMUT1. Ampicillin resistant, 6416 bp. 
This work. 
pLG4 3783 bp Bgl II fragment restricted from pLG3, ligated 
into the BamH I site of pMAH. Insert contains truncated 
SCO3234. Hygromycin resistant, 9295 bp.  
This work. 
pLG1 SCO3234 sequence PCR amplified (963 bp including 
start and stop codons) and ligated into pGEM T-Easy 
vector. Ampicillin resistant, 3978 bp. 
This work. 
pLG2 SCO3234 sequence restricted from pLG1 (939 bp) and 
ligated into pET-15b (Nde I/BamH I). Ampicillin 
resistant, 6637 bp. 
This work. 
 
 
 
 
 
 
 
 
 
Table 2. Primers and PCR products.  
 
Primer Sequence (5’-3’) Description Encompassing 
nucleotide 
coordinates  
AsnOF2 gcg cag ctc gag cgc gc 
 
Upstream asnO flanking region 
forward primer. XhoI site 
underlined. 
3587906 to 3587923 
AsnOR2 gtc cac gct gca gac cgg cc Upstream asnO flanking region 
reverse primer. Pst I site 
underlined. 
3586365 to 3586385 
AsnOF3 gag gac cgg cgc cga att ctc 
 
Downstream asnO flanking 
region forward primer. EcoR I 
site underlined. 
3590092 to 3590113 
AsnOR3 ctg cgc gaa ctc gag gcc c 
 
Downstream asnO flanking 
region reverse primer. Xho I 
site underlined. 
3588451 to 3588470 
29.05seqF2 ctg cgg ggg ctt ggc cgg t 
 
Forward primer flanking the 
deletion junction of truncated 
asnO.  
3588687 to 3588706 
29.05seqR2 cga cgg tgg acg gag gct ctg 
 
Reverse primer flanking the 
deletion junction of truncated 
asnO. 
3587662 to 3587683 
29.05F2 ggg ggc ttc tcg agt cag gc 
 
Forward primer flanking 
SCO3236. Xho I site 
underlined. 
3588682 to 3588702 
29.05R2 ggc tct gca tat ggc tgc gaa tg 
 
Reverse primer flanking 
SCO3236. Nde I site 
underlined. 
3587676 to 3587699 
HasPF1 att ctg cag agc cga tgg agc 
 
Upstream hasP flanking region 
forward primer. Pst I site 
underlined. 
3583076 to 3583089 
HasPR1 att cta gag gcc agc gcg atc 
agc 
Upstream hasP flanking region 
reverse primer. Xba I site 
underlined. 
3584874 to 3584890 
HasPF2 att cta gag ccc gca tcg agg 
tg 
Downstream hasP flanking 
region forward primer. Xba I 
site underlined. 
3585514 to 3585529 
HasPR2 att ctc gag ggg acg tac tgg Downstream hasP flanking 
region reverse primer. Xho I 
site underlined. 
3587424 to 3587436 
HasPKO1 gtc aac ggc atc agg atc aac 
tac t 
Forward primer flanking the 
deletion junction of truncated 
hasP.  
3584006 to 3584031 
HasPKO2 cta ctg gat gag cag ttg gtg 
gct g 
Reverse primer flanking the 
deletion junction of truncated 
hasP.  
3585799 to 3585824 
hasPseqF2 ggg cac tac ggc tac ctg ga Forward primer flanking the 3584741 to 3584760 
deletion junction of truncated 
hasP 
Cdapfow2 ata cgc gca tat gaa gac tga 
gtc cga t 
Forward primer flanking 
SCO3234. Nde I site 
underlined. 
3584822 to 3584839 
Cdaprev2 ata gga tcc gcg cac ttc acc g Reverse primer flanking 
SCO3234. BamH I site 
underlined. 
3585752 to 3585765 
 
 
 
 
 
 
 
